All
Learn to Advocate for the Cancer Community with Triage Cancer
Join Triage Cancer for their free webinar on Post-Election Advocacy: Getting Engaged.
Neoadjuvant Tyvyt With Chemo Improve Responses in Resectable, Locally Advanced ESCC
In resectable, locally advanced esophageal squamous cell carcinoma, neoadjuvant Tyvyt plus chemoradiotherapy led to an improvement in response rates.
When Cancer Makes You Cry, Cry It Out
Even stoics need to cry now and then. My advice from personal experience is this: it is okay to cry.
World Cancer Day Shines Light on Therapeutic Advancements in Cancer Care
Dr. John Oertle discussed the significance of World Cancer Day, raising awareness about cancer care advancements and improving patient outcomes.
Weight Gain Measurements May Be Underreported in ALK+ NSCLC Trials
Alecensa weight gain is underreported in ALK+ NSCLC trials, highlighting the need for increased awareness and proactive management of this side effect.
Tevimbra Plus Chemo May Be Safe, Effective in Advanced Gastric/GEJ Cancer
Frontline treatment with Tevimbra plus irinotecan, paclitaxel, oxaliplatin and 5-FU/leucovorin had promising efficacy and manageable safety in gastric/GEJ cancer.
Rybrevant Alone and in Combo With Chemo is Efficacious in Wildtype+ mCRC
Dr. Filippo Pietrantonio discusses OrigAMI-1 trial data which assessed Rybrevant in mutated, wild-type, non-HER2-amplified metastatic colorectal cancer.
Breast Cancer Sucks But Sometimes Thoughtfulness Can Make It Better
Breast cancer affected my looks and self-esteem, but I found small things could make a big difference in feeling pretty again.
Breaking Down Cancer Therapies Approved by the FDA in January 2025
Here is a select list of cancer therapies approved by the FDA throughout the month of January, featuring patient populations like AML, MDS and breast cancer.
Cabometyx Demonstrates PFS Benefit Versus Placebo in GI-NETs
Dr. Jonathan R. Strosberg, discussed results of the CABINET trial evaluating Cabometyx versus placebo in advanced gastrointestinal NETs.
ITM-11 Meets Phase 3 Trial Primary End Point of PFS in GEP-NETs
Topline results from the COMPETE trial showed that ITM-11 met the study’s primary end point of PFS in inoperable, progressive grade 1 or grade 2 GEP-NETs.
The Tap on the Shoulder: Cancer's Unexpected Call
After a second breast cancer diagnosis at 61, I faced 17 rounds of chemo, surgery and radiation, changing my perspective on life and leading to a new normal.
Tevimbra Plus Chemotherapy May Improve Survival in First-Line ESCC
Early and late responders with esophageal squamous cell carcinoma experienced comparable OS benefits with Tevimbra plus chemo in the RATIONALE-306 trial.
New Trial to Test Light Therapy Plus Keytruda in Head and Neck Cancer
A phase 3 trial is evaluating ASP-1929 photoimmunotherapy plus Keytruda in first-line treatment for recurrent head and neck squamous cell carcinoma.
Breaking Down the Safety of BCG in Patients With NMIBC
BCG therapy is associated with a high frequency of side effects in NMIBC; however, when used in sequential combination with chemo, fewer were reported.
Why Hope is Important For Patients with Chronic Lymphocytic Leukemia
Hope is crucial for those of us with chronic lymphocytic leukemia, or any cancer, helping us navigate the disease's challenges.
Dwyane Wade Talks Tumor Removal, Bachelorette Star’s Husband Cancer Diagnosis and More
From the reveal of NBA star Dwyane Wade’s cancer surgery to a Bachelorette star on her husband’s cancer diagnosis, here is this week’s top cancer news.
Keytruda and Lenvima Combo Misses OS Mark in HER2– Gastroesophageal Cancer
In the LEAP-015 trial, Keytruda and Lenvima plus chemo did not meet the primary end point of overall survival in HER2– gastroesophageal adenocarcinoma.
Galinpepimut-S Immunotherapy Has Preliminary Efficacy in Acute Myeloid Leukemia
Galinpepimut-S therapy showed specific T-Cell immune responses for patients with acute myeloid leukemia in remission following second-line salvage therapy.
Herceptin Combo Shows Limited Benefit in Gastric/GEJ Cancer
In the INNOVATION trial, adding Herceptin and Perjeta to chemotherapy increased toxicity in patients with HER2-positive gastric cancers.
Strutting Into Year 11 With Metastatic Breast Cancer
After living with metastatic breast cancer for 11 years, I reflect on my journey and plan to embrace the coming year with confidence and self-advocacy.
How Do Molecular Factors Impact Response to Immunotherapy in Kidney Cancer?
Dr. David A. Braun delved into the molecular factors which drive exceptional responses to immunotherapy in metastatic clear cell renal cell carcinoma.
Itovebi-Based Treatment Has OS Benefit in PIK3CA+ HR+/HER2– Breast Cancer
Among patients with advanced PIK3CA-mutated, HR-positive/HER2-negative breast cancer, Itovebi-based treatment generated positive overall survival results.
A Phase 1 Trial of Iadademstat Plus Vidaza Has Dosed a Patient With MDS
The first patient has been dosed in a phase 1 dose-finding clinical trial evaluating iadademstat with Vidaza in patients with myelodysplastic syndrome.
Opdivo Plus Yervoy Improves Outcomes in Metastatic Colorectal Cancer Subset
The combination of Opdivo and Yervoy is supported by updated results as a standard of care for MSI-H or dMMR metastatic colorectal cancer.
Ovarian Cancer Teaches Hard Life Lessons
Having a life-threatening disease reminds me daily to make the most of whatever time I have.
A Cancer Institution is Seeking to Address Food Insecurity in Patients With Cancer
Dr. Anna Arthur discusses the NOURISH trial, which aims to address food insecurity and malnutrition in patients with blood cancers undergoing treatment.
FDA Accepts sNDA for Welireg in Advanced Pheochromocytoma and Paraganglioma
The FDA has accepted a priority review sNDA for Welireg in adults and pediatric patients with advanced or metastatic pheochromocytoma and paraganglioma.
Breaking Down the CONVERGE Study of NBTXR3 in Stage 3 Unresectable NSCLC
The first participant has been dosed on the phase 2 CONVERGE study evaluating NBTXR3 in stage III, unresectable non–small cell lung cancer.
Brukinsa May Improve Efficacy Versus Imbruvica in R/R CLL and SLL
Brukinsa had a lower risk of disease progression or death versus Imbruvica, as well as a more favorable safety profile, in R/R CLL and SLL.
